Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Puszkiel A, Bauriaud-Mallet M, Bourgeois R, Dierickx L, Courbon F, Chatelut E.

Clin Pharmacokinet. 2018 May 8. doi: 10.1007/s40262-018-0674-1. [Epub ahead of print]


A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer.

Puszkiel A, Plé A, Huillard O, Noé G, Thibault C, Oudard S, Goldwasser F, Vidal M, Alexandre J, Blanchet B.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jul 15;1058:102-107. doi: 10.1016/j.jchromb.2017.04.014. Epub 2017 Apr 5.


Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.

Garlan F, Blanchet B, Kramkimel N, Puszkiel A, Golmard JL, Noe G, Dupin N, Laurent-Puig P, Vidal M, Taly V, Thomas-Schoemann A.

Target Oncol. 2017 Jun;12(3):365-371. doi: 10.1007/s11523-017-0491-8.


Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients.

Puszkiel A, Noé G, Boudou-Rouquette P, Cossec CL, Arrondeau J, Giraud JS, Thomas-Schoemann A, Alexandre J, Vidal M, Goldwasser F, Blanchet B.

J Pharm Biomed Anal. 2017 May 30;139:30-36. doi: 10.1016/j.jpba.2017.02.041. Epub 2017 Feb 24.


Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.

Noé G, Bellesoeur A, Thomas-Schoemann A, Rangarajan S, Naji F, Puszkiel A, Huillard O, Saidu N, Golmard L, Alexandre J, Goldwasser F, Blanchet B, Vidal M.

Oncotarget. 2016 Oct 11;7(41):67507-67520. doi: 10.18632/oncotarget.11686.


Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.

Puszkiel A, White-Koning M, Dupin N, Kramkimel N, Thomas-Schoemann A, Noé G, Chapuis N, Vidal M, Goldwasser F, Chatelut E, Blanchet B.

Pharmacol Res. 2016 Nov;113(Pt A):709-718. doi: 10.1016/j.phrs.2016.06.032. Epub 2016 Jul 1.


Supplemental Content

Loading ...
Support Center